EP1554284B1 - Verfahren zur herstellung der kristallform i von clopidogrel-hydrogensulphat - Google Patents

Verfahren zur herstellung der kristallform i von clopidogrel-hydrogensulphat Download PDF

Info

Publication number
EP1554284B1
EP1554284B1 EP03750270A EP03750270A EP1554284B1 EP 1554284 B1 EP1554284 B1 EP 1554284B1 EP 03750270 A EP03750270 A EP 03750270A EP 03750270 A EP03750270 A EP 03750270A EP 1554284 B1 EP1554284 B1 EP 1554284B1
Authority
EP
European Patent Office
Prior art keywords
solution
hydrogen sulphate
clopidogrel
formula
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP03750270A
Other languages
English (en)
French (fr)
Other versions
EP1554284A1 (de
Inventor
Miroslav Veverka
Stefan Vodny
Eva Veverkova
Josef Hajicek
Hana Stepankova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31954588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1554284(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of EP1554284A1 publication Critical patent/EP1554284A1/de
Application granted granted Critical
Publication of EP1554284B1 publication Critical patent/EP1554284B1/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the invention relates to a new method for manufacturing hydrogen sulphate (alpha S) of the alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester (clopidogrel hydrogen sulphate) in its crystalline Form I.
  • Hydrogen sulphate (alpha S) of the alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester (clopidogrel hydrogen sulphate) of formula I is an anti-thrombotic agent that has been described in patent CZ 274 420 ( EP 281 459 ), dealing with the technology for manufacturing dextrorotatory S enantiomer.
  • the manufacturing method disclosed in the cited patent dwells in reacting the racemic mixture with optically active camphor sulphonic acid and subsequent separating the diastereoisomer.
  • the respective salt of clopidogrel with camphor sulphonic acid is transformed with sodium hydrogen carbonate solution in methylene chloride environment into the optically active base, which is obtained by evaporation of the solvent.
  • the evaporation residue - the optically active base of clopidogrel - is dissolved in acetone, where it is transformed into hydrogen sulphate by adding drops of an equivalent amount of sulphuric acid, under cooling with crushed ice.
  • the melting temperature of the resulting precipitate is stated as 184 °C.
  • Example 6 of the application WO 03/035652 A similar method is described in Example 6 of the application WO 03/035652 . According to this method, reaction of the clopidogrel base and sulphuric acid is carried out in acetone; the product is crystallized and filtered. The filtrate is treated with further sulphuric acid in ethyl acetate, and further portion of the product is crystallized. The melting temperature of the complete product was 186.7 to 187.4 °C.
  • the process for obtaining Form II according to example 1A of this application dwells in introduction of the salt of clopidogrel with camphor sulphonic acid into methylene chloride and its transformation into the base with a solution of potassium carbonate. Methylene chloride is evaporated and the evaporation residue is dissolved in acetone. By adding sulphuric acid, the hydrogen sulphate precipitates out of acetone.
  • the present invention provides a reliable method for obtaining Form I of clopidogrel hydrogen sulphate without detectable impurity of Form II.
  • This invention relates to a method for manufacturing crystalline Form I of clopidogrel hydrogen sulphate, consisting in crystallisation or precipitation of this Form from a solvent selected from the series of C1-C5 alcohols or their esters with C1-C4 acids, optionally of mixtures of alcohols and esters.
  • the manufacturing method described in the prior art thus allows a non-specific preparation of Form I. It has now been found out that if clopidogrel hydrogen sulphate is allowed to crystallise by the procedure according to this invention, Form I having a high and defined content can be obtained in a reproducible way.
  • the substance of this invention is a process for manufacturing crystalline Form I of clopidogrel hydrogen sulphate, which method resides in:
  • crystalline Form I of clopidogrel hydrogen sulphate can be produced in an alternative procedure, residing in:
  • the mixture is stirred until the crystalline phase separates at a temperature between 10 and 15 °C for 1.5 to 2 hours, and then at -5 °C for 8 hours.
  • the product is filtered off on fritted glass S-2 and dried with a stream of air.
  • 1.7 g of clopidogrel hydrogen sulphate Form I with minimal polymorph purity of 98 % and having the melting point of 185 to 187 °C are obtained.
  • 0.5 g of clopidogrel hydrogen sulphate Form II, having the melting point of 177 to 179 °C, are separated out of the mother liquors upon standing at 25 °C.
  • clopidogrel hydrogen sulphate Form I showing the melting point of 184 to 186 °C
  • clopidogrel hydrogen sulphate Form II having the melting point of 177 to 179 °C, is separated upon standing at 25 °C.
  • clopidogrel base 56.9 g clopidogrel base are dissolved in 570 ml of n-butyl acetate and placed in a three-neck round flask, equipped with a thermometer, a KPG stirrer and a dropping funnel. Under mixing, the butyl acetate solution is cooled down to 0 to +5 °C in a water-and-ice bath. The solution is inoculated with crystals of clopidogrel Form I. Under intensive stirring, 9.71 ml of concentrated sulphuric acid (97%) (1.5 equiv.) are added dropwise into the cooled-down solution such that the temperature of the reaction mixture does not exceed +5 °C.
  • clopidogrel base 12.63 g clopidogrel base are dissolved in 126 ml of n-butyl acetate and placed in a three-neck round flask, equipped with a thermometer, a KPG stirrer and a dropping funnel. Under stirring, the butyl acetate solution is cooled down to 0 to +5 °C in a water-and-ice bath. The solution is inoculated with crystals of clopidogrel Form I. Under intensive stirring, 2.4 ml of concentrated sulphuric acid (98%) (1.1 equiv.) are added dropwise into the cooled-down solution such that the temperature of the reaction mixture does not exceed +5 °C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Claims (6)

  1. Verfahren zur Herstellung von Hydrogensulfat (alpha S) des Alpha-(2-chlorphenyl)-6,7-dihydrothieno[3,2]pyridrin-5(4H)-essigsäure-methylester (Clopidogrel Hydrogensulfat) der Formel I
    Figure imgb0003
     in Kristallinform I, dadurch gekennzeichnet, dass die Verbindung der Formel I aus einer Lösung von Clopidogrel in Form der freien Base oder Salz in einem aus einer Reihe von primären, sekundären oder tertiären C1-C5-Alkoholen oder deren Estern mit C1-C4 Carbonsäuren oder optional aus deren Mischungen gewählten Lösungsmittel herausgetrennt wird, unter der Bedingung, dass das Herstellungsverfahren, bestehend daraus, 98% Schwefelsäure zu der Clopidogrelbase in einer Lösung in Aceton bei 20-28°C hinzuzufügen, 5 Stunden umzurühren, bei Temperaturen zwischen 0-10°C abzukühlen, diese Temperatur für 2 Stunden zu halten, das Produkt zu filtern, dann 98% Schwefelsäure in Ethylacetat bei 20-28°C zu dem Filtrat über einen Zeitraum von einer Stunde hinzuzufügen und das Produkt nach 5-stündigem Umrühren zu filtern, mit Aceton zu waschen und 4 Stunden im Vakuumofen zwischen 50 und 55°C zu trocknen, ausgeschlossen wird.
  2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass die Verbindung der Formel I aus einer Lösung vom Clopidogrel Hydrogensulfat durch Abkühlen herauskristallisiert wird.
  3. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass die Verbindung der Formel I aus einer Lösung von ihrer Base oder ihrem Salz durch Hinzufügen von 0,6 bis 1,1 Äquivalente Schwefelsäure niedergeschlagen wird.
  4. Verfahren nach Anspruch 3, dadurch gekennzeichnet, dass die Verbindung der Formel I aus einer Lösung in einem C1-C5-Alkohol niedergeschlagen wird.
  5. Verfahren nach Anspruch 4, dadurch gekennzeichnet, dass die Ausfällung aus einer Lösung in 2-Propanol durchgeführt wird.
  6. Verfahren nach Anspruch 5, dadurch gekennzeichnet, dass die Ausfällung bei einer Temperatur zwischen -5 und 15°C durchgeführt wird und die Lösung mit Kristallen der Form 1 angeimpft wird.
EP03750270A 2002-08-27 2003-08-26 Verfahren zur herstellung der kristallform i von clopidogrel-hydrogensulphat Revoked EP1554284B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZ20022906 2002-08-27
CZ20022906A CZ297472B6 (cs) 2002-08-27 2002-08-27 Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
PCT/CZ2003/000049 WO2004020443A1 (en) 2002-08-27 2003-08-26 Method for manufacturing crystalline form i of clopidogrel hydrogen sulphate

Publications (2)

Publication Number Publication Date
EP1554284A1 EP1554284A1 (de) 2005-07-20
EP1554284B1 true EP1554284B1 (de) 2008-10-22

Family

ID=31954588

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03750270A Revoked EP1554284B1 (de) 2002-08-27 2003-08-26 Verfahren zur herstellung der kristallform i von clopidogrel-hydrogensulphat

Country Status (12)

Country Link
US (1) US7714133B2 (de)
EP (1) EP1554284B1 (de)
JP (1) JP2006502238A (de)
KR (1) KR20050058492A (de)
AT (1) ATE411998T1 (de)
AU (1) AU2003269673A1 (de)
CA (1) CA2495823A1 (de)
CZ (1) CZ297472B6 (de)
DE (1) DE60324301D1 (de)
EA (1) EA007977B1 (de)
PL (1) PL373578A1 (de)
WO (1) WO2004020443A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012300A1 (en) * 2003-08-04 2005-02-10 Wockhardt Limited A novel process for the manufacture of (+)-(s)-clopidogrel bisulfate form-i
DE10337773A1 (de) * 2003-08-13 2005-03-24 Krka Tovarna Zdravil, D.D. Kristallisation von festen Formen von Clopidogrel-Additionssalzen
ATE455778T1 (de) * 2003-11-03 2010-02-15 Cadila Healthcare Ltd Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
CA2562532C (en) * 2004-04-09 2010-02-16 Hanmi Pharm. Co., Ltd. Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
EA010198B1 (ru) * 2004-04-19 2008-06-30 Крка, Товарна Здравил, Д.Д., Ново Место Способы получения полиморфной формы i гидросульфата клопидогрела
ZA200608035B (en) * 2004-04-20 2008-07-30 Sanofi Aventis Clopidogrel salt and polymorphic forms thereof
UA83919C2 (en) * 2004-04-20 2008-08-26 Санофи Авентис Polymorphic forms of methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate hydrobromide, clopidrogel hydrobromide
EP1693375A1 (de) * 2005-02-21 2006-08-23 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung von Clopidrogel hydrogen sulfat in Form I
US7772398B2 (en) 2005-03-11 2010-08-10 Dr. Reddy's Laboratories, Inc. Process for making crystalline form I of clopidogrel hydrogen sulphate
WO2007017886A1 (en) * 2005-08-11 2007-02-15 Arch Pharmalabs Limited Novel process for preparation of clopidogrel bisulphate polymorphic form i
US20080226579A1 (en) 2005-09-21 2008-09-18 Chong Kun Dang Pharmaceutical Corp. Novel Resinate Complex of S-Clopidogrel and Production Method Thereof
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
EP2114957A4 (de) * 2007-01-29 2011-06-08 Ipca Lab Ltd Verfahren zur herstellung von kristallinem clopidogrelhydrogensulfat der form i
JP5681485B2 (ja) 2007-04-27 2015-03-11 サイデックス・ファーマシューティカルズ・インコーポレイテッド クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法
EP2107061A1 (de) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Herstellungsverfahren für optisch angereichertes Clopidogrel
WO2009156279A2 (en) * 2008-06-24 2009-12-30 Zach System S.P.A. Process for the preparation of clopidogrel hydrogen sulfate crystalline form i
CA2761455C (en) 2009-05-13 2018-06-12 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
WO2011042804A2 (en) 2009-10-08 2011-04-14 Jubliant Life Sciences Limited An improved process for the preparation of clopidogrel hydrogen sulfate form i
KR101130445B1 (ko) * 2009-10-29 2012-03-27 동아제약주식회사 클로피도그랠 황산수소염 ⅰ형 제조방법
WO2011051976A2 (en) 2009-10-30 2011-05-05 Matrix Laboratories Ltd An improved process for the preparation of clopidogrel bisulfate form i
EP2491044A4 (de) * 2009-11-09 2013-04-24 Pharmazell Gmbh Verbessertes verfahren zur herstellung von clopiodogrel-bisulfat in der kristallform 1
WO2011125069A1 (en) 2010-03-22 2011-10-13 Rpg Life Sciences Limited A process for preparation of crystalline form i of clopidogrel bisulfate
CN102558194A (zh) * 2010-12-11 2012-07-11 山东方明药业股份有限公司 一种硫酸氢氯吡格雷i型的制备方法
CN102875568B (zh) * 2012-09-06 2015-12-09 苏州晶云药物科技有限公司 制备(+)-(s)-氯吡格雷硫酸氢盐纯晶型i的方法
KR101710922B1 (ko) 2015-06-03 2017-02-28 경동제약 주식회사 클로피도그렐 황산염 결정형 i형의 제조방법
CN107118221B (zh) * 2017-05-24 2021-09-07 常州制药厂有限公司 一种硫酸氢氯吡格雷晶型i制备方法
CN107163060B (zh) * 2017-05-24 2021-03-02 常州制药厂有限公司 一种硫酸氢氯吡格雷晶型ii制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035652A1 (en) * 2001-10-26 2003-05-01 Merck Generics [Uk] Limited A PROCESS FOR PREPARING ENANTIOMERICALLY PURE α-PHENYL-α-(6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES
WO2003051362A2 (en) * 2001-12-18 2003-06-26 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US6767913B2 (en) * 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) * 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
JP4072005B2 (ja) * 2002-06-12 2008-04-02 日本電波工業株式会社 温度補償水晶発振器
WO2005012300A1 (en) * 2003-08-04 2005-02-10 Wockhardt Limited A novel process for the manufacture of (+)-(s)-clopidogrel bisulfate form-i

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035652A1 (en) * 2001-10-26 2003-05-01 Merck Generics [Uk] Limited A PROCESS FOR PREPARING ENANTIOMERICALLY PURE α-PHENYL-α-(6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES
WO2003051362A2 (en) * 2001-12-18 2003-06-26 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate

Also Published As

Publication number Publication date
US7714133B2 (en) 2010-05-11
CZ20022906A3 (en) 2004-05-12
CZ297472B6 (cs) 2006-12-13
PL373578A1 (en) 2005-09-05
WO2004020443A1 (en) 2004-03-11
US20060041136A1 (en) 2006-02-23
EA007977B1 (ru) 2007-02-27
CA2495823A1 (en) 2004-03-11
EA200500310A1 (ru) 2005-08-25
EP1554284A1 (de) 2005-07-20
DE60324301D1 (de) 2008-12-04
ATE411998T1 (de) 2008-11-15
JP2006502238A (ja) 2006-01-19
KR20050058492A (ko) 2005-06-16
AU2003269673A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
EP1554284B1 (de) Verfahren zur herstellung der kristallform i von clopidogrel-hydrogensulphat
US7629465B2 (en) Industrial process for preparation of Clopidogrel hydrogen sulphate
US20060183907A1 (en) Novel process for the manufacture of (+)-(s)-clopidogrel bisulfate form-1
EP1656381B1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
WO2008118030A1 (en) Process for preparation of pure polymorphic form 1 of clopidogrel hydrogensulfate
EP2216329A1 (de) Verfahren zur Herstellung von Tadalafil
US7772398B2 (en) Process for making crystalline form I of clopidogrel hydrogen sulphate
AU2009264395B2 (en) Process for the preparation of clopidogrel hydrogen sulfate crystalline form I
US20100081839A1 (en) Process for preparation of crystalline clopidogrel hydrogen sulphate form i
ITMI20090663A1 (it) Procedimento per la purificazione di paliperidone
WO2007102037A2 (en) A PROCESS FOR THE PREPARATION OF POLYMORPH FORM I OF (S)-(+)-METHYL-α-(2-CHLOROPHENYL)-6,7-DYHIDRO-THIENO-[3,2-c]PYRIDINE-5(4H)-ACETATE HYDROGEN SULFATE
SK12852002A3 (sk) Spôsob výroby clopidogrelu hydrogensulfátu kryštalickej formy I
EP1856127A1 (de) Verfahren zur racemisierung des r-(-)-isomers von (2-chlorphenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4h)essigsäuremethylester
WO2006130852A1 (en) Recovery of clopidogrel bisulfate
JP2007516166A (ja) 血小板凝集阻害剤の無晶形の製法

Legal Events

Date Code Title Description
TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

17P Request for examination filed

Effective date: 20050111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20070828

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60324301

Country of ref document: DE

Date of ref document: 20081204

Kind code of ref document: P

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090202

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E004876

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090323

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20090617

Year of fee payment: 7

Ref country code: EE

Payment date: 20090615

Year of fee payment: 7

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: STRAWMAN LIMITED

Effective date: 20090722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090122

26 Opposition filed

Opponent name: EGIS GYOGYSZERGYAR NYRT

Effective date: 20090722

Opponent name: STRAWMAN LIMITED

Effective date: 20090722

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090720

Year of fee payment: 7

Ref country code: HU

Payment date: 20090622

Year of fee payment: 7

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20091005

Year of fee payment: 7

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090123

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E002942

Country of ref document: EE

Effective date: 20100831

LTLA Lt: lapse of european patent or patent extension

Effective date: 20100826

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100827

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60324301

Country of ref document: DE

Effective date: 20110301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110729

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20110729

Year of fee payment: 9

Ref country code: SK

Payment date: 20110712

Year of fee payment: 9

Ref country code: RO

Payment date: 20110826

Year of fee payment: 9

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: EGIS GYOGYSZERGYAR NYRT

Effective date: 20090722

Opponent name: STRAWMAN LIMITED

Effective date: 20090722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100831

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: STRAWMAN LIMITED

Effective date: 20090722

Opponent name: EGIS GYOGYSZERGYAR NYRT

Effective date: 20090722

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 4892

Country of ref document: SK

Effective date: 20120826

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120826

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: STRAWMAN LIMITED

Effective date: 20090722

RDAE Information deleted related to despatch of communication that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSDREV1

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120826

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

27W Patent revoked

Effective date: 20140526

RDAC Information related to revocation of patent modified

Free format text: ORIGINAL CODE: 0009299REVO

RDAD Information modified related to despatch of communication that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSCREV1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: SK

Ref legal event code: MC4A

Ref document number: E 4892

Country of ref document: SK

Effective date: 20140526

REG Reference to a national code

Ref country code: EE

Ref legal event code: MF4A

Ref document number: E002942

Country of ref document: EE

Effective date: 20140930

R27W Patent revoked (corrected)

Effective date: 20140607